CompletedNot Applicable

Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers

Democratic Republic of the Congo133 participantsStarted 2021-12-13

Plain-language summary

During the previous Ebola virus disease (EVD) outbreaks, the institute National de Recherche Biomédicale (INRB) and other institutional's staff in Democratic Republic of the Congo (DRC) got vaccinated with the rVSV-ZEBOV vaccine. However, the longevity of Ebola virus (EBOV)-specific immune responses after vaccination has not been studied extensively (only 1-2 years) nor comprehensively (only humoral), despite the wide use of this vaccine. With the re-emergence of Ebola in North-Kivu from a previously vaccinated individual, and the new planned vaccination campaign (considering homologous booster doses for previously vaccinated HCW) in light of the new outbreak in Beni, assessing the persistence and quality of vaccine-induced anti-EBOV immune responses is pertinent and timely.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subject is willing and able to give informed consent for participation in the study * Subject can be contacted by phone, email or physical address * Subject is aged 18 years or above * Subject must have a ID card (or other identification document) For vaccinated group: \- Subject must be receiving the rVSV-ZEBOV vaccine (first or second dose) at time of inclusion OR has received a first rVSV-ZEBOV vaccine dose prior to inclusion of which vaccination date and brand is known For unvaccinated group (controls): Subject must NOT have received the rVSV-ZEBOV vaccine nor had any prior close contact with EBOV patients Exclusion Criteria: * Subject was previously diagnosed with EVD * Subject has any contraindication to venipuncture, as determined by clinical judgement

What they're measuring

EBOV glycoprotein (GP)-specific T and B cell Spot Forming Units

Timeframe: Day 0

EBOV glycoprotein (GP)-specific T and B cell Spot Forming Units

Timeframe: Day 7

EBOV glycoprotein (GP)-specific T and B cell Spot Forming Units

Timeframe: Day 28

Trial details

NCT IDNCT05313139

SponsorInstitute of Tropical Medicine, Belgium

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-02-01

View on ClinicalTrials.gov More Immune Response trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.